Current strategies for targeted delivery of bio-active drug molecules in the treatment of brain tumor

References

• Andlin-Sobocki P, Jönsson B, Wittchen HU, Olesen J. Cost of disorders of the brain in Europe. Eur J Neurol 2005;12:1–27
   PubMed Web of Science ®Google Scholar
• Rohilla R, Garg T, Bariwal J, et al. Development, optimization and characterization of glycyrrhetinic acid-chitosan nanoparticles of atorvastatin for liver targeting. Drug Deliv 2014. [Epub ahead of print]. doi: 10.3109/10717544.2014.977460
   Web of Science ®Google Scholar
• Ricci M, Blasi P, Giovagnoli S, Rossi C. Delivering drugs to the central nervous system: a medicinal chemistry or a pharmaceutical technology issue? Curr Med Chem 2006;13:1757–75
   PubMed Web of Science ®Google Scholar
• Begley DJ, Brightman MW. Structural and functional aspects of the blood-brain barrier. In: Prokai L, Prokai-Tatrai K, eds. Peptide transport and delivery into the central nervous system. Basel: Springer; 2003
   Google Scholar
• Dallas S, Miller DS, Bendayan R. Multidrug resistance-associated proteins: expression and function in the central nervous system. Pharmacol Rev 2006;58:140–61
   PubMed Web of Science ®Google Scholar
• Deeken JF, Löscher W. The blood-brain barrier and cancer: transporters, treatment, and Trojan horses. Clin Cancer Res 2007;13:1663–74
   PubMed Web of Science ®Google Scholar
• Lee G, Dallas S, Hong M, Bendayan R. Drug transporters in the central nervous system: brain barriers and brain parenchyma considerations. Pharmacol Rev 2001;53:569–96
   PubMed Web of Science ®Google Scholar
• Nies AT. The role of membrane transporters in drug delivery to brain tumors. Cancer Lett 2007;254:11–29
   PubMed Web of Science ®Google Scholar
• Persidsky Y, Ramirez SH, Haorah J, Kanmogne GD. Blood–brain barrier: structural components and function under physiologic and pathologic conditions. J Neuroimmune Pharmacol 2006;1:223–36
   PubMed Web of Science ®Google Scholar
• Tamai I, Tsuji A. Transporter-mediated permeation of drugs across the blood–brain barrier. J Pharm Sci 2000;89:1371–88
   PubMed Web of Science ®Google Scholar
• Abbott NJ, Rönnbäck L, Hansson E. Astrocyte–endothelial interactions at the blood–brain barrier. Nat Rev Neurosci 2006;7:41–53
   PubMed Web of Science ®Google Scholar
• Zlokovic BV. The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron 2008;57:178–201
   PubMed Web of Science ®Google Scholar
• Packhaeuser C, Schnieders J, Oster C, Kissel T. In situ forming parenteral drug delivery systems: an overview. Eur J Pharm Biopharm 2004;58:445–55
   PubMed Web of Science ®Google Scholar
• Soppimath KS, Aminabhavi TM, Kulkarni AR, Rudzinski WE. Biodegradable polymeric nanoparticles as drug delivery devices. J Control Release 2001;70:1–20
   PubMed Web of Science ®Google Scholar
• Deli MA, Ábrahám CS, Kataoka Y, Niwa M. Permeability studies on in vitro blood–brain barrier models: physiology, pathology, and pharmacology. Cell Mol Neurobiol 2005;25:59–127
   PubMed Web of Science ®Google Scholar
• Butt AM, Jones HC, Abbott NJ. Electrical resistance across the blood-brain barrier in anaesthetized rats: a developmental study. J Physiol 1990;429:47–62
   PubMed Web of Science ®Google Scholar
• Garcia-Garcia E, Andrieux K, Gil S, Couvreur P. Colloidal carriers and blood–brain barrier (BBB) translocation: a way to deliver drugs to the brain? Int J Pharm 2005;298:274–92
   PubMed Web of Science ®Google Scholar
• Behin A, Hoang-Xuan K, Carpentier AF, Delattre J-Y. Primary brain tumours in adults. Lancet 2003;361:323–31
   PubMed Web of Science ®Google Scholar
• Pardridge WM. Blood–brain barrier delivery. Drug Discov Today 2007a;12:54–61
   PubMed Web of Science ®Google Scholar
• Wolburg H, Wolburg-Buchholz K, Liebner S, Engelhardt B. Claudin-1, claudin-2 and claudin-11 are present in tight junctions of choroid plexus epithelium of the mouse. Neurosci Lett 2001;307:77–80
   PubMed Web of Science ®Google Scholar
• Pardridge WM. Drug delivery to the brain. J Cereb Blood Flow Metab 1997;17:713–31
   PubMed Web of Science ®Google Scholar
• Saito Y, Wright E. Bicarbonate transport across the frog choroid plexus and its control by cyclic nucleotides. J Physiol 1983;336:635–48
   PubMed Web of Science ®Google Scholar
• Pappas GD, Tennyson VM. An electron microscopic study of the passage of colloidal particles from the blood vessels of the ciliary processes and choroid plexus of the rabbit. J Cell Biol 1962;15:227–39
   PubMed Web of Science ®Google Scholar
• Colgan OC, Collins NT, Ferguson G, et al. Influence of basolateral condition on the regulation of brain microvascular endothelial tight junction properties and barrier function. Brain Res 2008;1193:84–92
   PubMed Web of Science ®Google Scholar
• Juillerat-Jeanneret L. The targeted delivery of cancer drugs across the blood–brain barrier: chemical modifications of drugs or drug-nanoparticles? Drug Discov Today 2008;13:1099–106
   PubMed Web of Science ®Google Scholar
• Olivier J-C. Drug transport to brain with targeted nanoparticles. NeuroRx 2005;2:108–19
   PubMedGoogle Scholar
• Joó F. The blood-brain barrier in vitro: the second decade. Neurochem Int 1993;23:499–521
   PubMed Web of Science ®Google Scholar
• Donelli M, Zucchetti M, D'Incalci M. Do anticancer agents reach the tumor target in the human brain? Cancer Chemother Pharmacol 1992;30:251–60
   PubMed Web of Science ®Google Scholar
• Pardridge WM, Triguero D, Yang J, Cancilla PA. Comparison of in vitro and in vivo models of drug transcytosis through the blood-brain barrier. J Pharmacol Exp Ther 1990;253:884–91
   PubMed Web of Science ®Google Scholar
• Brightman MW. Ultrastructure of brain endothelium. In: Bradbury MWB, ed. Physiology and pharmacology of the blood-brain barrier. Berlin: Springer; 1992
   Google Scholar
• Brightman M, Reese T. Junctions between intimately apposed cell membranes in the vertebrate brain. J Cell Biol 1969;40:648–77
   PubMed Web of Science ®Google Scholar
• Hawkins BT, Davis TP. The blood-brain barrier/neurovascular unit in health and disease. Pharmacol Rev 2005;57:173–85
   PubMed Web of Science ®Google Scholar
• Reese T, Karnovsky MJ. Fine structural localization of a blood-brain barrier to exogenous peroxidase. J Cell Biol 1967;34:207–17
   PubMed Web of Science ®Google Scholar
• Saunders N, Habgood M, Dziegielewska K. Barrier mechanisms in the brain, II. Immature brain. Clin Exp Pharmacol Physiol 1999;26:85–91
   PubMed Web of Science ®Google Scholar
• Saunders NR, Ek CJ, Habgood MD, Dziegielewska KM. Barriers in the brain: a renaissance? Trends Neurosci 2008;31:279–86
   PubMed Web of Science ®Google Scholar
• Saunders NR, Knott GW, Dziegielewska KM. Barriers in the immature brain. Cell Mol Neurobiol 2000;20:29–40
   PubMed Web of Science ®Google Scholar
• Stewart PA. Endothelial vesicles in the blood–brain barrier: are they related to permeability? Cell Mol Neurobiol 2000;20:149–63
   PubMed Web of Science ®Google Scholar
• Cecchelli R, Berezowski V, Lundquist S, et al. Modelling of the blood–brain barrier in drug discovery and development. Nat Rev Drug Discov 2007;6:650–61
   PubMed Web of Science ®Google Scholar
• Newton HB. Advances in strategies to improve drug delivery to brain tumors. Expert Rev Neurother 2006;6:1495–509
   PubMedGoogle Scholar
• Begley DJ. The blood-brain barrier: principles for targeting peptides and drugs to the central nervous system. J Pharm Pharmacol 1996;48:136–46
   PubMed Web of Science ®Google Scholar
• Gao H, Pang Z, Jiang X. Targeted delivery of nano-therapeutics for major disorders of the central nervous system. Pharm Res 2013;30:2485–98
   PubMed Web of Science ®Google Scholar
• Piper HM. Cell culture techniques in heart and vessel research. Berlin: Springer-Verlag; 1990
   Google Scholar
• Kimelberg HK, Norenberg MD. Astrocytes. Sci Am 1989;260:66–72, 74, 76
   PubMed Web of Science ®Google Scholar
• Kruh GD, Belinsky MG. The MRP family of drug efflux pumps. Oncogene 2003;22:7537–52
   PubMed Web of Science ®Google Scholar
• Löscher W, Potschka H. Drug resistance in brain diseases and the role of drug efflux transporters. Nat Rev Neurosci 2005;6:591–602
   PubMed Web of Science ®Google Scholar
• Ramge P, Unger RE, Oltrogge JB, et al. Polysorbate-80 coating enhances uptake of polybutylcyanoacrylate (PBCA)-nanoparticles by human and bovine primary brain capillary endothelial cells. Eur J Neurosci 2000;12:1931–40
   PubMed Web of Science ®Google Scholar
• Sun J-J, Xie L, Liu X-D. Transport of carbamazepine and drug interactions at blood-brain barrier. Acta Pharmacol Sin 2006;27:249–53
   PubMed Web of Science ®Google Scholar
• Fischer H, Gottschlich R, Seelig A. Blood-brain barrier permeation: molecular parameters governing passive diffusion. J Membr Biol 1998;165:201–11
   PubMed Web of Science ®Google Scholar
• Koziara JM, Lockman PR, Allen DD, Mumper RJ. Paclitaxel nanoparticles for the potential treatment of brain tumors. J Control Release 2004;99:259–69
   PubMed Web of Science ®Google Scholar
• Hau P, Fabel K, Baumgart U, et al. Pegylated liposomal doxorubicin-efficacy in patients with recurrent high-grade glioma. Cancer 2004;100:1199–207
   PubMed Web of Science ®Google Scholar
• Han H-K, Amidon GL. Targeted prodrug design to optimize drug delivery. AAPS PharmSci 2000;2:48–58
   Google Scholar
• Pardridge WM. Drug targeting to the brain. Pharm Res 2007;24:1733–44
   PubMed Web of Science ®Google Scholar
• King GL, Johnson SM. Receptor-mediated transport of insulin across endothelial cells. Science 1985;227:1583–6
   PubMed Web of Science ®Google Scholar
• Maratos-Flier E, Kao C-YY, Verdin EM, King GL. Receptor-mediated vectorial transcytosis of epidermal growth factor by Madin-Darby canine kidney cells. J Cell Biol 1987;105:1595–601
   PubMed Web of Science ®Google Scholar
• Roberts RL, Fine RE, Sandra A. Receptor-mediated endocytosis of transferrin at the blood-brain barrier. J Cell Sci 1993;104:521–32
   PubMed Web of Science ®Google Scholar
• Kumagai A, Eisenberg JB, Pardridge W. Absorptive-mediated endocytosis of cationized albumin and a beta-endorphin-cationized albumin chimeric peptide by isolated brain capillaries. Model system of blood-brain barrier transport. J Biol Chem 1987;262:15214–19
   PubMed Web of Science ®Google Scholar
• Sai Y, Kajita M, Tamai I, et al. Adsorptive-mediated endocytosis of a basic peptide in enterocyte-like Caco-2 cells. Am J Physiol Gastrointest Liver Physiol 1998;275:G514–20
   PubMed Web of Science ®Google Scholar
• Bareford LM, Swaan PW. Endocytic mechanisms for targeted drug delivery. Adv Drug Deliv Rev 2007;59:748–58
   PubMed Web of Science ®Google Scholar
• Vyas S, Sihorkar V. Endogenous carriers and ligands in non-immunogenic site-specific drug delivery. Adv Drug Deliv Rev 2000;43:101–64
   PubMed Web of Science ®Google Scholar
• Pardridge WM. Blood-brain barrier drug targeting: the future of brain drug development. Mol Interv 2003;3:90–105
   PubMedGoogle Scholar
• Demeule M, Currie JC, Bertrand Y, et al. Involvement of the low-density lipoprotein receptor-related protein in the transcytosis of the brain delivery vector Angiopep-2. J Neurochem 2008;106:1534–44
   PubMed Web of Science ®Google Scholar
• Murata H, Futami J, Kitazoe M, et al. Intracellular delivery of glutathione S-transferase-fused proteins into mammalian cells by polyethylenimine–glutathione conjugates. J Biochem 2008;144:447–55
   PubMed Web of Science ®Google Scholar
• Cornford EM, Young D, Paxton JW, et al. Melphalan penetration of the blood-brain barrier via the neutral amino acid transporter in tumor-bearing brain. Cancer Res 1992;52:138–43
   PubMed Web of Science ®Google Scholar
• Umezawa F, Eto Y. Liposome targeting to mouse brain: mannose as a recognition marker. Biochem Biophys Res Commun 1988;153:1038–44
   PubMed Web of Science ®Google Scholar
• Benoit J-P, Faisant N, Venier-Julienne M-C, Menei P. Development of microspheres for neurological disorders: from basics to clinical applications. J Control Release 2000;65:285–96
   PubMed Web of Science ®Google Scholar
• Menei P, Benoit J-P, Boisdron-Celle M, et al. Drug targeting into the central nervous system by stereotactic implantation of biodegradable microspheres. Neurosurgery 1994;34:1058–64
   PubMed Web of Science ®Google Scholar
• Mittal S, Cohen A, Maysinger D. In vitro effects of brain derived neurotrophic factor released from microspheres. Neuroreport 1994;5:2577–82
   PubMed Web of Science ®Google Scholar
• Brem H, Ewend MG, Piantadosi S, et al. The safety of interstitial chemotherapy with BCNU-loaded polymer followed by radiation therapy in the treatment of newly diagnosed malignant gliomas: phase I trial. J Neuro-oncol 1995;26:111–23
   PubMed Web of Science ®Google Scholar
• Ewend MG, Williams JA, Tabassi K, et al. Local delivery of chemotherapy and concurrent external beam radiotherapy prolongs survival in metastatic brain tumor models. Cancer Res 1996;56:5217–23
   PubMed Web of Science ®Google Scholar
• Valtonen S, Timonen U, Toivanen P, et al. Interstitial chemotherapy with carmustine-loaded polymers for high-grade gliomas: a randomized double-blind study. Neurosurgery 1997;41:44–9
   PubMed Web of Science ®Google Scholar
• Sheleg SV, Korotkevich EA, Zhavrid EA, et al. Local chemotherapy with cisplatin-depot for glioblastoma multiforme. J Neuro-oncol 2002;60:53–9
   PubMed Web of Science ®Google Scholar
• Vukelja SJ, Anthony SP, Arseneau JC, et al. Phase 1 study of escalating-dose OncoGel (R)(ReGel (R)/paclitaxel) depot injection, a controlled-release formulation of paclitaxel, for local management of superficial solid tumor lesions. Anti-Cancer Drugs 2007;18:283–9
   PubMed Web of Science ®Google Scholar
• Boer GJ, van der Woude TP, Kruisbrink J, van Heerikhuize J. Successful ventricular application of the miniaturized controlled-delivery Accurel technique for sustained enhancement of cerebrospinal fluid peptide levels in the rat. J Neurosci Methods 1984;11:281–9
   PubMed Web of Science ®Google Scholar
• Fortin D, Desjardins A, Benko A, et al. Enhanced chemotherapy delivery by intraarterial infusion and blood-brain barrier disruption in malignant brain tumors. Cancer 2005;103:2606–15
   PubMed Web of Science ®Google Scholar
• Dave N, Gudelsky GA, Desai PB. The pharmacokinetics of letrozole in brain and brain tumor in rats with orthotopically implanted C6 glioma, assessed using intracerebral microdialysis. Cancer Chemother Pharmacol 2013;72:349–57
   PubMed Web of Science ®Google Scholar
• Remsen LG, Trail PA, Hellström I, et al. Enhanced delivery improves the efficacy of a tumor-specific doxorubicin immunoconjugate in a human brain tumor xenograft model. Neurosurgery 2000;46:704–9
   PubMed Web of Science ®Google Scholar
• Muldoon LL, Soussain C, Jahnke K, et al. Chemotherapy delivery issues in central nervous system malignancy: a reality check. J Clin Oncol 2007;25:2295–305
   PubMed Web of Science ®Google Scholar
• Blanchette M, Fortin D. Blood-brain barrier disruption in the treatment of brain tumors. Methods Mol Biol 2011;686:447–63
   PubMedGoogle Scholar
• Lossinsky A, Vorbrodt A, Wisniewski H. Scanning and transmission electron microscopic studies of microvascular pathology in the osmotically impaired blood-brain barrier. J Neurocytol 1995;24:795–806
   PubMedGoogle Scholar
• Salahuddin T, Johansson B, Kalimo H, Olsson Y. Structural changes in the rat brain after carotid infusions of hyperosmolar solutions. Acta Neuropathol 1988;77: 5–13
   PubMed Web of Science ®Google Scholar
• Kroll RA, Neuwelt EA. Outwitting the blood-brain barrier for therapeutic purposes: osmotic opening and other means. Neurosurgery 1998;42:1083–99
   PubMed Web of Science ®Google Scholar
• de Boer A, Gaillard P. In vitro models of the blood-brain barrier: when to use which? Curr Med Chem 2002;2:203–9
   Google Scholar
• Cosolo WC, Martinello P, Louis W, Christophidis N. Blood-brain barrier disruption using mannitol: time course and electron microscopy studies. Am J Physiol 1989;256:R443–7
   PubMed Web of Science ®Google Scholar
• De Vries HE, Blom-Roosemalen M, Oosten MV, et al. The influence of cytokines on the integrity of the blood-brain barrier in vitro. J Neuroimmunol 1996;64:37–43
   PubMed Web of Science ®Google Scholar
• Black KL, Cloughesy T, Huang S-C, et al. Intracarotid infusion of RMP-7, a bradykinin analog, and transport of gallium-68 ethylenediamine tetraacetic acid into human gliomas. J Neurosurg 1997;86:603–9
   PubMed Web of Science ®Google Scholar
• Emerich DF, Snodgrass P, Pink M, et al. Central analgesic actions of loperamide following transient permeation of the blood brain barrier with Cereport™(RMP-7). Brain Res 1998;801:259–66
   PubMed Web of Science ®Google Scholar
• Bartus R. The blood-brain barrier as a target for pharmacological modulation. Curr Opin Drug Discov Dev 1999;2:152–67
   PubMedGoogle Scholar
• Mertsch K, Maas J. Blood-brain barrier penetration and drug development from an industrial point of view. Curr Med Chem 2002;2:187–201
   Google Scholar
• Nakagawa H, Groothuis D, Blasberg RG. The effect of graded hypertonic intracarotid infusions on drug delivery to experimental RG-2 gliomas. Neurology 1984;34:1571–81
   PubMed Web of Science ®Google Scholar
• Neuwelt EA, Goldman D, Dahlborg S, et al. Primary CNS lymphoma treated with osmotic blood-brain barrier disruption: prolonged survival and preservation of cognitive function. J Clin Oncol 1991;9:1580–90
   PubMed Web of Science ®Google Scholar
• Grossman SA, Trump DL, Chen DC, et al. Cerebrospinal fluid flow abnormalities in patients with neoplastic meningitis: an evaluation using 111indium-DTPA ventriculography. Am J Med 1982;73:641–7
   PubMed Web of Science ®Google Scholar
• Begley DJ, Squires LK, Zloković BV, et al. Permeability of the blood-brain barrier to the immunosuppressive cyclic peptide cyclosporin A. J Neurochem 1990;55:1222–30
   PubMed Web of Science ®Google Scholar
• Mamelak AN, Rosenfeld S, Bucholz R, et al. Phase I single-dose study of intracavitary-administered iodine-131-TM-601 in adults with recurrent high-grade glioma. J Clin Oncol 2006;24:3644–50
   PubMed Web of Science ®Google Scholar
• Krewson CE, Klarman ML, Saltzman WM. Distribution of nerve growth factor following direct delivery to brain interstitium. Brain Res 1995;680:196–206
   PubMed Web of Science ®Google Scholar
• Matsukado K, Inamura T, Nakano S, et al. Enhanced tumor uptake of carboplatin and survival in glioma-bearing rats by intracarotid infusion of bradykinin analog, RMP-7. Neurosurgery 1996;39:125–34
   PubMed Web of Science ®Google Scholar
• Tetsuya T, Yoshiharu D, Yuko K, et al. Determination of in vivo steady-state unbound drug concentration in the brain interstitial fluid by microdialysis. Int J Pharm 1992;81:143–52
   Google Scholar
• Olson L, Nordberg A, von Holst H, et al. Nerve growth factor affects11C-nicotine binding, blood flow, EEG, and verbal episodic memory in an Alzheimer patient (case report). J Neural Transm 1992;4:79–95
   Web of Science ®Google Scholar
• Menacherry S, Hubert W, JusticeJr. JB. In vivo calibration of microdialysis probes for exogenous compounds. Analyt Chem 1992;64:577–83
   PubMed Web of Science ®Google Scholar
• Erben M, Decker S, Franke H, Galla H-J. Electrical resistance measurements on cerebral capillary endothelial cells – a new technique to study small surface areas. J Biochem Biophys Methods 1995;30:227–38
   PubMedGoogle Scholar
• Gath U, Hakvoort A, Wegener J, et al. Porcine choroid plexus cells in culture: expression of polarized phenotype, maintenance of barrier properties and apical secretion of CSF-components. Eur J Cell Biol 1997;74:68–78
   PubMed Web of Science ®Google Scholar
• Sawyer AJ, Piepmeier JM, Saltzman WM. Cancer issue: new methods for direct delivery of chemotherapy for treating brain tumors. Yale J Biol Med 2006;79:141–52
   PubMedGoogle Scholar
• Guerin C, Olivi A, Weingart JD, et al. Recent advances in brain tumor therapy: local intracerebral drug delivery by polymers. Invest New Drugs 2004;22:27–37
   PubMed Web of Science ®Google Scholar
• Raza SM, Pradilla G, Legnani FG, et al. Local delivery of antineoplastic agents by controlled-release polymers for the treatment of malignant brain tumours. Expert Opin Biol Ther 2005;5:477–94
   PubMed Web of Science ®Google Scholar
• Bobo RH, Laske DW, Akbasak A, et al. Convection-enhanced delivery of macromolecules in the brain. Proc Natl Acad Sci USA 1994;91:2076–80
   PubMed Web of Science ®Google Scholar
• Vogelbaum MA. Convection enhanced delivery for treating brain tumors and selected neurological disorders: symposium review. J Neuro-oncol 2007;83:97–109
   PubMed Web of Science ®Google Scholar
• Sampson JH, Akabani G, Archer GE, et al. Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumors. Neuro Oncol 2008;10:320–9
   PubMed Web of Science ®Google Scholar
• Ashby LS, Shapiro WR. Intra-arterial cisplatin plus oral etoposide for the treatment of recurrent malignant glioma: a phase II study. J Neuro-oncol 2001;51:67–86
   PubMed Web of Science ®Google Scholar
• Dropcho EJ, Rosenfeld SS, Vitek J, et al. Phase II study of intracarotid or selective intracerebral infusion of cisplatin for treatment of recurrent anaplastic gliomas. J Neuro-oncol 1998;36:191–8
   PubMed Web of Science ®Google Scholar
• Neuwelt EA. Mechanisms of disease: the blood-brain barrier. Neurosurgery 2004;54:131–42
   PubMed Web of Science ®Google Scholar
• Jahnke K, Kraemer DF, Knight KR, et al. Intraarterial chemotherapy and osmotic blood-brain barrier disruption for patients with embryonal and germ cell tumors of the central nervous system. Cancer 2008;112:581–8
   PubMed Web of Science ®Google Scholar
• Gundersen S, Lote K, Watne K. A retrospective study of the value of chemotherapy as adjuvant therapy to surgery and radiotherapy in grade 3 and 4 gliomas. Eur J Cancer 1998;34:1565–9
   PubMed Web of Science ®Google Scholar
• Hirano Y, Mineura K, Mizoi K, Tomura N. Therapeutic results of intra-arterial chemotherapy in patients with malignant glioma. Int J Oncol 1998;13:537–79
   PubMed Web of Science ®Google Scholar
• Joshi S, Reif R, Wang M, et al. Intra-arterial mitoxantrone delivery in rabbits: an optical pharmacokinetic study. Neurosurgery 2011;69:706–12; discussion 712
   PubMed Web of Science ®Google Scholar
• Rapoport SI. Osmotic opening of the blood–brain barrier: principles, mechanism, and therapeutic applications. Cell Mol Neurobiol 2000;20:217–30
   PubMed Web of Science ®Google Scholar
• Brown MT, Coleman RE, Friedman AH, et al. Intrathecal 131I-labeled antitenascin monoclonal antibody 81C6 treatment of patients with leptomeningeal neoplasms or primary brain tumor resection cavities with subarachnoid communication: phase I trial results. Clin Cancer Res 1996;2:963–72
   PubMed Web of Science ®Google Scholar
• Blacklock JB, Wright DC, Dedrick RL, et al. Drug streaming during intra-arterial chemotherapy. J Neurosurg 1986;64:284–91
   PubMed Web of Science ®Google Scholar
• Bargoni A, Cavalli R, Zara GP, et al. Transmucosal transport of tobramycin incorporated in solid lipid nanoparticles (SLN) after duodenal administration to rats. Part II – tissue distribution. Pharmacol Res 2001;43:497–502
   PubMed Web of Science ®Google Scholar
• Cavalli R, Zara GP, Caputo O, et al. Transmucosal transport of tobramycin incorporated in SLN after duodenal administration to rats. Part I – A pharmacokinetic study. Pharmacol Res 2000;42:541–5
   PubMed Web of Science ®Google Scholar
• Fundarò A, Cavalli R, Bargoni A, et al. Non-stealth and stealth solid lipid nanoparticles (SLN) carrying doxorubicin: pharmacokinetics and tissue distribution after iv administration to rats. Pharmacol Res 2000;42:337–43
   PubMed Web of Science ®Google Scholar
• Zara GP, Cavalli R, Bargoni A, et al. Intravenous administration to rabbits of non-stealth and stealth doxorubicin-loaded solid lipid nanoparticles at increasing concentrations of stealth agent: pharmacokinetics and distribution of doxorubicin in brain and other tissues. J Drug Target 2002;10:327–35
   PubMed Web of Science ®Google Scholar
• de Lange E, Danhof M, De Boer AG, Breimer DD. Methodological considerations of intracerebral microdialysis in pharmacokinetic studies on drug transport across the blood–brain barrier. Brain Res Rev 1997;25:27–49
   PubMed Web of Science ®Google Scholar
• Pardridge WM. Non-invasive drug delivery to the human brain using endogenous blood–brain barrier transport systems. Pharm Sci Technol Today 1999;2:49–59
   PubMedGoogle Scholar
• Shi N, Pardridge WM. Noninvasive gene targeting to the brain. Proc Natl Acad Sci USA 2000;97:7567–72
   PubMed Web of Science ®Google Scholar
• Zhang Y-F, Boado RJ, Pardridge WM. Absence of toxicity of chronic weekly intravenous gene therapy with pegylated immunoliposomes. Pharm Res 2003;20:1779–85
   PubMed Web of Science ®Google Scholar
• Nutt J, Burchiel K, Comella C, et al. Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. Neurology 2003;60:69–73
   PubMed Web of Science ®Google Scholar
• Ko YT, Bhattacharya R, Bickel U. Liposome encapsulated polyethylenimine/ODN polyplexes for brain targeting. J Control Release 2009;133:230–7
   PubMed Web of Science ®Google Scholar
• Miller L, Meythaler J, Peduzzi J. Direct central nervous system catheter and temperature control system. EP Patent 1,600,186; 2005
   Google Scholar
• Raghavan R, Brady ML, Rodríguez-Ponce MI, et al. Convection-enhanced delivery of therapeutics for brain disease, and its optimization. Neurosurg Focus 2006;20:E12
   PubMedGoogle Scholar
• Chen MY, Lonser RR, Morrison PF, et al. Variables affecting convection-enhanced delivery to the striatum: a systematic examination of rate of infusion, cannula size, infusate concentration, and tissue-cannula sealing time. J Neurosurg 1999;90:315–20
   PubMed Web of Science ®Google Scholar
• Bauman M, Gillies G, Raghavan R, et al. Physical characterization of neurocatheter performance in a brain phantom gelatin with nanoscale porosity: steady-state and oscillatory flows. Nanotechnology 2004;15:92–104
   Web of Science ®Google Scholar
• Morrison PF, Chen MY, Chadwick RS, et al. Focal delivery during direct infusion to brain: role of flow rate, catheter diameter, and tissue mechanics. Am J Physiol 1999;277:R1218–29
   PubMed Web of Science ®Google Scholar
• Linninger AA, Somayaji MR, Mekarski M, Zhang L. Prediction of convection-enhanced drug delivery to the human brain. J Theor Biol 2008;250:125–38
   PubMed Web of Science ®Google Scholar
• de Lange E, De Vries J, Zurcher C, et al. The use of intracerebral microdialysis for the determination of pharmacokinetic profiles of anticancer drugs in tumor-bearing rat brain. Pharm Res 1995;12:1924–31
   PubMed Web of Science ®Google Scholar
• Olson J, Blakeley J, Grossman S, et al. Differences in the distribution of methotrexate into high grade gliomas following intravenous administration, as monitored by microdialysis, are associated with blood brain barrier integrity. J Clin Oncol 2006;24:1548–59
   Google Scholar
• Portnow J, Badie B, Xi B, et al. Intracerebral microdialysis for determination of the neuropharmacokinetics and neuropharmacodynamics of temozolomide in patients with primary or metastatic brain tumors. J Clin Oncol 2007;25:2074–82
   Google Scholar
• Casacó A, López G, García I, et al. Phase I single-dose study of intracavitary-administered Nimotuzumab labeled with 188-Re in adult recurrent high-grade glioma. Cancer Biol Ther 2008;7:333–9
   PubMed Web of Science ®Google Scholar
• Mcrae-Degueurce A, Hjorth S, Dillon DL, et al. Implantable microencapsulated dopamine (DA): a new approach for slow-release DA delivery into brain tissue. Neurosci Lett 1988;92:303–9
   PubMed Web of Science ®Google Scholar
• Rousseau J, Barth RF, Moeschberger ML, Elleaume H. Efficacy of intracerebral delivery of carboplatin in combination with photon irradiation for treatment of F98 glioma-bearing rats. Int J Radiat Oncol Biol Phys 2009;73:530–6
   PubMed Web of Science ®Google Scholar
• Jayachandra Babu R, Dayal PP, Pawar K, Singh M. Nose-to-brain transport of melatonin from polymer gel suspensions: a microdialysis study in rats. J Drug Target 2011;19:731–40
   PubMed Web of Science ®Google Scholar
• de Lange E, De Boer BA, Breimer DD. Microdialysis for pharmacokinetic analysis of drug transport to the brain. Adv Drug Deliv Rev 1999;36:211–27
   PubMed Web of Science ®Google Scholar
• Parsons L, JusticeJr. J. Quantitative approaches to in vivo brain microdialysis. Crit Rev Neurobiol 1993;8:189–220
   Web of Science ®Google Scholar
• Devineni D, Klein-Szanto A, Gallo JM. In vivo microdialysis to characterize drug transport in brain tumors: analysis of methotrexate uptake in rat glioma-2 (RG-2)-bearing rats. Cancer Chemother Pharmacol 1996;38:499–507
   PubMed Web of Science ®Google Scholar
• Nakashima M, Shibata S, Tokunaga Y, et al. In-vivo microdialysis study of the distribution of cisplatin into brain tumour tissue after intracarotid infusion in rats with 9L malignant glioma. J Pharm Pharmacol 1997;49:777–80
   PubMed Web of Science ®Google Scholar
• Dykstra KH, Hsiao JK, Morrison PF, et al. Quantitative examination of tissue concentration profiles associated with microdialysis. J Neurochem 1992;58:931–40
   PubMed Web of Science ®Google Scholar
• Groothuis DR, Ward S, Schlageter KE, et al. Changes in blood-brain barrier permeability associated with insertion of brain cannulas and microdialysis probes. Brain Res 1998;803:218–30
   PubMed Web of Science ®Google Scholar
• Morgan ME, Singhal D, Anderson BD. Quantitative assessment of blood-brain barrier damage during microdialysis. J Pharmacol Exp Ther 1996;277:1167–76
   PubMed Web of Science ®Google Scholar
• Westergren I, Nyström B, Hamberger A, Johansson BB. Intracerebral dialysis and the blood-brain barrier. J Neurochem 1995;64:229–34
   PubMed Web of Science ®Google Scholar
• Fung LK, Ewend MG, Sills A, et al. Pharmacokinetics of interstitial delivery of carmustine, 4-hydroperoxycyclophosphamide, and paclitaxel from a biodegradable polymer implant in the monkey brain. Cancer Res 1998;58:672–84
   PubMed Web of Science ®Google Scholar
• Yang FY, Lin YL, Chou FI, et al. Pharmacokinetics of BPA in gliomas with ultrasound induced blood-brain barrier disruption as measured by microdialysis. PLoS One 2014;9:e100104
   Google Scholar
• Hannon GJ. RNA interference. Nature 2002;418:244–51
   PubMed Web of Science ®Google Scholar
• Hébert SS, De Strooper B. Molecular biology. miRNAs in neurodegeneration. Science (New York, NY) 2007;317:1179–80
   Web of Science ®Google Scholar
• Zhang Y, Jeong Lee H, Boado RJ, Pardridge WM. Receptor-mediated delivery of an antisense gene to human brain cancer cells. J Gene Med 2002;4:183–94
   PubMed Web of Science ®Google Scholar
• Daneman R, Barres B. Permeability of blood-brain barrier. WO Patent 2007137303, 2007
   Google Scholar
• Patel N, Addo RT, Ubale R, et al. The effect of antisense to NF-kappaB in an albumin microsphere formulation on the progression of left-ventricular remodeling associated with chronic volume overload in rats. J Drug Target 2014;22:796–804
   PubMed Web of Science ®Google Scholar
• Liu CH, Kim YR, Ren JQ, et al. Imaging cerebral gene transcripts in live animals. J Neurosci 2007;27:713–22
   PubMed Web of Science ®Google Scholar
• Masotti A, Vicennati P, Boschi F, et al. A novel near-infrared indocyanine dye−polyethylenimine conjugate allows DNA delivery imaging in vivo. Bioconjug Chem 2008;19:983–7
   PubMed Web of Science ®Google Scholar
• Béduneau A, Saulnier P, Benoit J-P. Active targeting of brain tumors using nanocarriers. Biomaterials 2007;28:4947–67
   PubMed Web of Science ®Google Scholar
• Schneider T, Becker A, Ringe K, et al. Brain tumor therapy by combined vaccination and antisense oligonucleotide delivery with nanoparticles. J Neuroimmunol 2008;195:21–7
   PubMed Web of Science ®Google Scholar
• Ljubimova JY, Fujita M, Khazenzon NM, et al. Nanoconjugate based on polymalic acid for tumor targeting. Chem Biol Interact 2008;171:195–203
   PubMed Web of Science ®Google Scholar
• Ljubimova JY, Fujita M, Ljubimov AV, et al. Poly (malic acid) nanoconjugates containing various antibodies and oligonucleotides for multitargeting drug delivery. Nanomedicine 2008;3:247–65
   PubMed Web of Science ®Google Scholar
• Bawarski WE, Chidlowsky E, Bharali DJ, Mousa SA. Emerging nanopharmaceuticals. Nanomedicine 2008;4:273–82
   PubMed Web of Science ®Google Scholar
• Jain K. Nanomedicine: application of nanobiotechnology in medical practice. Med Princ Pract 2008;17:89–101
   PubMed Web of Science ®Google Scholar
• Kim YK, Xing L, Chen BA, et al. Aerosol delivery of programmed cell death protein 4 using polysorbitol-based gene delivery system for lung cancer therapy. J Drug Target 2014;22:829–38
   PubMed Web of Science ®Google Scholar
• Ren H, Boulikas T, Söling A, et al. Immunogene therapy of recurrent glioblastoma multiforme with a liposomally encapsulated replication-incompetent Semliki forest virus vector carrying the human interleukin-12 gene – a phase I/II clinical protocol. J Neuro-oncol 2003;64:147–54
   PubMed Web of Science ®Google Scholar
• Cusack. Jr JC, Tanabe KK. Cancer gene therapy. Surg Oncol Clin North Am 1998;7:421–69
   PubMedGoogle Scholar
• Dickson PV, Nathwani AC, Davidoff AM. Delivery of antiangiogenic agents for cancer gene therapy. Technol Cancer Res Treat 2005;4:331–41
   PubMed Web of Science ®Google Scholar
• Robson T, Worthington J, McKeown S, Hirst D. Radiogenic therapy: novel approaches for enhancing tumor radiosensitivity. Technol Cancer Res Treat 2005;4:343–61
   PubMed Web of Science ®Google Scholar
• Dent P, Yacoub A, Park M, et al. Searching for a cure: gene therapy for glioblastoma. Cancer Biol Ther 2008;7:1335–40
   PubMed Web of Science ®Google Scholar
• Lang FF, Bruner JM, Fuller GN, et al. Phase I trial of adenovirus-mediated p53 gene therapy for recurrent glioma: biological and clinical results. J Clin Oncol 2003;21:2508–18
   PubMed Web of Science ®Google Scholar
• Klatzmann D, Valery CA, Bensimon G, et al. A phase I/II study of herpes simplex virus type 1 thymidine kinase “suicide” gene therapy for recurrent glioblastoma. Hum Gene Ther 1998;9:2595–604
   PubMed Web of Science ®Google Scholar
• Rainov NG. A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. Hum Gene Ther 2000;11:2389–401
   PubMed Web of Science ®Google Scholar
• Colombo F, Barzon L, Franchin E, et al. Combined HSV-TK/IL-2 gene therapy in patients with recurrent glioblastoma multiforme: biological and clinical results. Cancer Gene Ther 2005;12:835–48
   PubMed Web of Science ®Google Scholar
• Eck SL, Alavi J, Judy K, et al. Treatment of recurrent or progressive malignant glioma with a recombinant adenovirus expressing human interferon-beta (H5. 010CMVhIFN-beta): a phase I trial. Hum Gene Ther 2001;12:97–113
   PubMed Web of Science ®Google Scholar
• Okada H, Pollack IF, Lieberman F, et al. Gene therapy of malignant gliomas: a pilot study of vaccination with irradiated autologous glioma and dendritic cells admixed with IL-4 transduced fibroblasts to elicit an immune response. Hum Gene Ther 2001;12:575–95
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zhu C, Pardridge WM. Antisense gene therapy of brain cancer with an artificial virus gene delivery system. Mol Ther 2002;6:67–72
   PubMed Web of Science ®Google Scholar
• Hattori Y, Maitani Y. Folate-linked lipid-based nanoparticle for targeted gene delivery. Curr Drug Deliv 2005;2:243–52
   PubMedGoogle Scholar
• Lu W, Sun Q, Wan J, et al. Cationic albumin–conjugated pegylated nanoparticles allow gene delivery into brain tumors via intravenous administration. Cancer Res 2006;66:11878–87
   PubMed Web of Science ®Google Scholar
• Zhang Y, Calon F, Zhu C, et al. Intravenous nonviral gene therapy causes normalization of striatal tyrosine hydroxylase and reversal of motor impairment in experimental parkinsonism. Hum Gene Ther 2003;14:1–12
   PubMed Web of Science ®Google Scholar
• Hatakeyama H, Akita H, Kogure K, et al. Development of a novel systemic gene delivery system for cancer therapy with a tumor-specific cleavable PEG-lipid. Gene Ther 2006;14:68–77
   PubMed Web of Science ®Google Scholar
• Green NM. Avidin. Adv Protein Chem 1974;29:85–133
   Google Scholar
• Sood A, Panchagnula R. Peroral route: an opportunity for protein and peptide drug delivery. Chem Rev 2001;101:3275–304
   PubMed Web of Science ®Google Scholar
• Vandermeulen GW, Klok HA. Peptide/protein hybrid materials: enhanced control of structure and improved performance through conjugation of biological and synthetic polymers. Macromol Biosci 2004;4:383–98
   PubMed Web of Science ®Google Scholar
• Neuwelt EA. Method for diagnostically imaging lesions in the brain inside a blood-brain barrier. Google Patents; 1991
   Google Scholar
• Wu D, Yang J, & Pardridge WM. Drug targeting of a peptide radiopharmaceutical through the primate blood-brain barrier in vivo with a monoclonal antibody to the human insulin receptor. Journal of Clinical Investigation 1997;100:1804–12
   PubMed Web of Science ®Google Scholar
• Pardridge WM, Boado RJ. Drug delivery of antisense oligonucleotides and peptides to tissues in vivo and to cells using avidin-biotin technology. Google Patents; 2001
   Google Scholar
• Pardridge WM, Wu D, Sakane T. Combined use of carboxyl-directed protein pegylation and vector-mediated blood-brain barrier drug delivery system optimizes brain uptake of brain-derived neurotrophic factor following intravenous administration. Pharm Res 1998;15:576–82
   PubMed Web of Science ®Google Scholar
• Wu G, Barth RF, Yang W, et al. Targeted delivery of methotrexate to epidermal growth factor receptor-positive brain tumors by means of cetuximab (IMC-C225) dendrimer bioconjugates. Mol Cancer Ther 2006;5:52–9
   PubMed Web of Science ®Google Scholar
• Arwert E, Hingtgen S, Figueiredo J-L, et al. Visualizing the dynamics of EGFR activity and antiglioma therapies in vivo. Cancer Res 2007;67:7335–42
   PubMed Web of Science ®Google Scholar
• Ren H, Yang B, Rainov NG. Receptor tyrosine kinases as therapeutic targets in malignant glioma. Rev Recent Clin Trials 2007;2:87–101
   PubMedGoogle Scholar
• Weppler SA, Li Y, Dubois L, et al. Expression of EGFR variant vIII promotes both radiation resistance and hypoxia tolerance. Radiother Oncol 2007;83:333–9
   PubMed Web of Science ®Google Scholar
• Aaron J, Nitin N, Travis K, et al. Plasmon resonance coupling of metal nanoparticles for molecular imaging of carcinogenesis in vivo. J Biomed Opt 2007;12:034007
   PubMed Web of Science ®Google Scholar
• Faillot T, Magdelénat H, Mady E, et al. A phase I study of an anti-epidermal growth factor receptor monoclonal antibody for the treatment of malignant gliomas. Neurosurgery 1996;39:478–83
   PubMed Web of Science ®Google Scholar
• Stragliotto G, Vega F, Stasiecki P, et al. Multiple infusions of anti-epidermal growth factor receptor (EGFR) monoclonal antibody (EMD 55 900) in patients with recurrent malignant gliomas. Eur J Cancer 1996;32:636–40
   Web of Science ®Google Scholar
• Ramos TC, Figueredo J, Catala M, et al. Treatment of high-grade glioma patients with the humanized anti-epidermal growth factor receptor (EGFR) antibody h-R3: report from a phase I/II trial. Cancer Biol Ther 2006;5:375–9
   PubMed Web of Science ®Google Scholar
• Wygoda Z, Kula D, Bierzynska-Macyszynz G, et al. Use of monoclonal anti-EGFR antibody in the radioimmunotherapy of malignant gliomas in the context of EGFR expression in grade III and IV tumors. Hybridoma 2006;25:125–32
   PubMed Web of Science ®Google Scholar
• Combs SE, Heeger S, Haselmann R, et al. Treatment of primary glioblastoma multiforme with cetuximab, radiotherapy and temozolomide (GERT)–phase I/II trial: study protocol. BMC Cancer 2006;6:133
   PubMed Web of Science ®Google Scholar
• Kreuter J. Nanoparticulate systems for brain delivery of drugs. Adv Drug Deliv Rev 2001;47:65–81
   PubMed Web of Science ®Google Scholar
• Yamamoto H, Kuno Y, Sugimoto S, et al. Surface-modified PLGA nanosphere with chitosan improved pulmonary delivery of calcitonin by mucoadhesion and opening of the intercellular tight junctions. J Control Release 2005;102:373–81
   PubMed Web of Science ®Google Scholar
• Cohen H, Levy R, Gao J, et al. Sustained delivery and expression of DNA encapsulated in polymeric nanoparticles. Gene Ther 2000;7:1896–905
   PubMed Web of Science ®Google Scholar
• Anderson RG, Brown MS, Goldstein JL. Role of the coated endocytic vesicle in the uptake of receptor-bound low density lipoprotein in human fibroblasts. Cell 1977;10:351–64
   PubMed Web of Science ®Google Scholar
• Bickel U, Yoshikawa T, Pardridge WM. Delivery of peptides and proteins through the blood–brain barrier. Adv Drug Deliv Rev 2001;46:247–79
   PubMed Web of Science ®Google Scholar
• Pardridge WM. Blood-brain barrier biology and methodology. J Neurovirol 1999;5:556–69
   PubMed Web of Science ®Google Scholar
• Engelhardt B. Molecular mechanisms involved in T cell migration across the blood–brain barrier. J Neural Transm 2006;113:477–85
   PubMed Web of Science ®Google Scholar
• Banks W, Kastin A, Ehrensing C. Endogenous peptide Tyr-Pro-Trp-Gly-NH2 (Tyr-W-MIF-1) is transported from the brain to the blood by peptide transport system-1. J Neurosci Res 1993;35:690–5
   PubMed Web of Science ®Google Scholar
• Allen DD, Geldenhuys WJ. Molecular modeling of blood–brain barrier nutrient transporters: in silico basis for evaluation of potential drug delivery to the central nervous system. Life Sci 2006;78:1029–33
   PubMed Web of Science ®Google Scholar
• Tsuji A. Small molecular drug transfer across the blood-brain barrier via carrier-mediated transport systems. NeuroRx 2005;2:54–62
   PubMedGoogle Scholar
• Gynther M, Laine K, Ropponen J, et al. Large neutral amino acid transporter enables brain drug delivery via prodrugs. J Med Chem 2008;51:932–6
   PubMed Web of Science ®Google Scholar
• Siegal T, Zylber-Katz E. Strategies for increasing drug delivery to the brain. Clin Pharmacokinet 2002;41:171–86
   PubMed Web of Science ®Google Scholar
• Cole S, Bhardwaj G, Gerlach J, et al. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 1992;258:1650–4
   PubMed Web of Science ®Google Scholar
• Begley DJ. Delivery of therapeutic agents to the central nervous system: the problems and the possibilities. Pharmacol Ther 2004;104:29–45
   PubMed Web of Science ®Google Scholar
• Keir ST, Dewhirst MW, Kirkpatrick JP, et al. Cellular redox modulator, ortho Mn(III) meso-tetrakis(N-n-hexylpyridinium-2-yl)porphyrin, MnTnHex-2-PyP(5+) in the treatment of brain tumors. Anticancer Agents Med Chem 2011;11:202–12
   PubMed Web of Science ®Google Scholar
• Namba H, Iwadate Y, Iyo M, et al. Glucose and methionine uptake by rat brain tumor treated with prodrug-activated gene therapy. Nucl Med Biol 1998;25:247–50
   PubMed Web of Science ®Google Scholar
• Savolainen J, Edwards JE, Morgan ME, et al. Effects of a P-glycoprotein inhibitor on brain and plasma concentrations of anti-human immunodeficiency virus drugs administered in combination in rats. Drug Metab Dispos 2002;30:479–82
   PubMed Web of Science ®Google Scholar
• Pignatello R, Pantò V, Salmaso S, et al. Flurbiprofen derivatives in Alzheimer’s disease: synthesis, pharmacokinetic and biological assessment of lipoamino acid prodrugs. Bioconjug Chem 2007;19:349–57
   PubMed Web of Science ®Google Scholar
• Begley DJ. Efflux mechanisms in the central nervous system: a powerful influence on drug distribution within the brain. In: Sharma HS, ed. Blood-spinal cord and brain barriers in health and disease. New York: Academic Press; 2004b:83–97
   Google Scholar
• Blakeley J. Drug delivery to brain tumors. Curr Neurol Neurosci Rep 2008;8:235–41
   PubMed Web of Science ®Google Scholar
• Breedveld P, Beijnen JH, Schellens JH. Use of P-glycoprotein and BCRP inhibitors to improve oral bioavailability and CNS penetration of anticancer drugs. Trends Pharmacol Sci 2006;27:17–24
   PubMed Web of Science ®Google Scholar
• Kabanov AV, Batrakova EV, Miller DW. Pluronic® block copolymers as modulators of drug efflux transporter activity in the blood–brain barrier. Adv Drug Deliv Rev 2003;55:151–64
   PubMed Web of Science ®Google Scholar
• Litman T, Skovsgaard T, Stein WD. Pumping of drugs by P-glycoprotein: a two-step process? J Pharmacol Exp Ther 2003;307:846–53
   PubMed Web of Science ®Google Scholar
• Sauna ZE, Ambudkar SV. Characterization of the catalytic cycle of ATP hydrolysis by human P-glycoprotein the two ATP hydrolysis events in a single catalytic cycle are kinetically similar but affect different functional outcomes. J Biol Chem 2001;276:11653–61
   PubMed Web of Science ®Google Scholar
• Wang F, Zhou F, Kruh GD, Gallo JM. Influence of blood-brain barrier efflux pumps on the distribution of vincristine in brain and brain tumors. Neuro Oncol 2010;12:1043–9
   PubMed Web of Science ®Google Scholar
• Regina A, Demeule M, Che C, et al. Antitumour activity of ANG1005, a conjugate between paclitaxel and the new brain delivery vector Angiopep-2. Br J Pharmacol 2008;155:185–97
   PubMed Web of Science ®Google Scholar
• Jones AR, Shusta EV. Blood–brain barrier transport of therapeutics via receptor-mediation. Pharm Res 2007;24:1759–71
   PubMed Web of Science ®Google Scholar
• Karkan D, Pfeifer C, Vitalis TZ, et al. A unique carrier for delivery of therapeutic compounds beyond the blood-brain barrier. PLoS One 2008;3:e2469
   PubMed Web of Science ®Google Scholar
• Waldeck W, Wiessler M, Ehemann V, et al. TMZ-BioShuttle – a reformulated Temozolomide. Int J Med Sci 2008;5:273–84
   PubMedGoogle Scholar
• Nam JP, Park JK, Son DH, et al. Evaluation of polyethylene glycol-conjugated novel polymeric anti-tumor drug for cancer therapy. Colloids Surf B Biointerfaces 2014;120:168–75
   PubMed Web of Science ®Google Scholar
• Cserr H, Patlak C. Secretion and bulk flow of interstitial fluid. In: Bradbury MWB, ed. Physiology and pharmacology of the blood-brain barrier. Berlin: Springer; 1992
   Google Scholar
• Laquintana V, Trapani A, Denora N, et al. New strategies to deliver anticancer drugs to brain tumors. Expert Opin Drug Deliv 2009;6:1017–32
   PubMed Web of Science ®Google Scholar
• Modgill V, Garg T, Goyal AK, Rath G. Transmucosal delivery of linagliptin for the treatment of type-2 diabetes mellitus by ultra-thin nanofibers. Curr Drug Deliv 2014. [Epub ahead of print]. doi: 10.2174/1567201811666141117144332
   Web of Science ®Google Scholar
• Fellner S, Bauer B, Miller DS, et al. Transport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo. J Clin Invest 2002;110:1309–18
   PubMed Web of Science ®Google Scholar
• Gupta S. QSAR studies on drugs acting at the central nervous system. Chem Rev 1989;89:1765–800
   Web of Science ®Google Scholar
• Hansch C, Leo A, Hoekman D. Exploring QSAR: hydrophobic, electronic, and steric constants. Washington, DC: American Chemical Society; 1995
   Google Scholar
• van de Waterbeemd H, Smith DA, Beaumont K, Walker DK. Property-based design: optimization of drug absorption and pharmacokinetics. J Med Chem 2001;44:1313–33
   PubMed Web of Science ®Google Scholar
• Patel M, Souto EB, Singh KK. Advances in brain drug targeting and delivery: limitations and challenges of solid lipid nanoparticles. Expert Opin Drug Deliv 2013;10:889–905
   PubMed Web of Science ®Google Scholar
• Rösler A, Vandermeulen GW, Klok H-A. Advanced drug delivery devices via self-assembly of amphiphilic block copolymers. Adv Drug Deliv Rev 2012;53:95–108
   Web of Science ®Google Scholar
• Chaudhary S, Garg T, Murthy RS, et al. Recent approaches of lipid-based delivery system for lymphatic targeting via oral route. J Drug Target 2014;22:871–82
   PubMed Web of Science ®Google Scholar
• Tang J, Fu H, Kuang Q, et al. Liposomes co-modified with cholesterol anchored cleavable PEG and octaarginines for tumor targeted drug delivery. J Drug Target 2014;22:313–26
   PubMed Web of Science ®Google Scholar
• Gagandeep Garg T, Malik B, Rath G, Goyal AK. Development and characterization of nano-fiber patch for the treatment of glaucoma. Eur J Pharm Sci 2014;53:10–16
   PubMed Web of Science ®Google Scholar
• Qin Y, Li ZW, Yang Y, et al. Liposomes formulated with fMLP-modified cholesterol for enhancing drug concentration at inflammatory sites. J Drug Target 2014;22:165–74
   PubMed Web of Science ®Google Scholar
• Garg T. Current nanotechnological approaches for an effective delivery of bio-active drug molecules in the treatment of acne. Artif Cells Nanomed Biotechnol 2014. [Epub ahead of print]. doi: 10.3109/21691401.2014.916715
   Web of Science ®Google Scholar
• Chrai SS, Murari R, Ahmad I. Liposomes (a review) – Part one: manufacturing issues. Biopharm – the applied technologies of biopharmaceutical development. Pharm Technol Eur 2001;14:10–38
   Google Scholar
• Garg T, Goyal AK. Iontophoresis: drug delivery system by applying an electrical potential across the skin. Drug Deliv Lett 2012;2:270–80
   Google Scholar
• Garg T, Goyal AK. Liposomes: targeted and controlled delivery system. Drug Deliv Lett 2014;4:62–71
   Google Scholar
• Garg T, Goyal AK. Medicated chewing gum: patient compliance oral drug delivery system. Drug Deliv Lett 2014;4:72–8
   Google Scholar
• Garg T, Goyal AK. Biomaterial-based scaffolds – current status and future directions. Expert Opin Drug Deliv 2014;11:767–89
   PubMed Web of Science ®Google Scholar
• Lim HJ, Cho EC, Shim J, et al. Polymer-associated liposomes as a novel delivery system for cyclodextrin-bound drugs. J Colloid Interface Sci 2008;320:460–8
   PubMed Web of Science ®Google Scholar
• Pardridge WM. Vector-mediated drug delivery to the brain. Adv Drug Deliv Rev 1999;36:299–321
   PubMed Web of Science ®Google Scholar
• Rahman A, Husain SR, Siddiqui J, et al. Liposome-mediated modulation of multidrug resistance in human HL-60 leukemia cells. J Natl Cancer Inst 1992;84:1909–15
   PubMed Web of Science ®Google Scholar
• Allen TM. Long-circulating (sterically stabilized) liposomes for targeted drug delivery. Trends Pharmacol Sci 1994;15:215–20
   PubMed Web of Science ®Google Scholar
• McNeeley KM, Annapragada A, Bellamkonda RV. Decreased circulation time offsets increased efficacy of PEGylated nanocarriers targeting folate receptors of glioma. Nanotechnology 2007;18:385101
   Web of Science ®Google Scholar
• Ishida T, Atobe K, Wang X, Kiwada H. Accelerated blood clearance of PEGylated liposomes upon repeated injections: effect of doxorubicin-encapsulation and high-dose first injection. J Control Release 2006;115:251–8
   PubMed Web of Science ®Google Scholar
• McNeeley KM, Karathanasis E, Annapragada AV, Bellamkonda RV. Masking and triggered unmasking of targeting ligands on nanocarriers to improve drug delivery to brain tumors. Biomaterials 2009;30:3986–95
   PubMed Web of Science ®Google Scholar
• Szebeni J, Baranyi L, Savay S, et al. Role of complement activation in hypersensitivity reactions to doxil and hynic PEG liposomes: experimental and clinical studies. J Liposome Res 2002;12:165–72
   PubMed Web of Science ®Google Scholar
• Qiu Y, Gao Y, Hu K, Li F. Enhancement of skin permeation of docetaxel: a novel approach combining microneedle and elastic liposomes. J Control Release 2008;129:144–50
   PubMed Web of Science ®Google Scholar
• Jia Y, Joly H, Omri A. Liposomes as a carrier for gentamicin delivery: development and evaluation of the physicochemical properties. Int J Pharm 2008;359:254–63
   PubMed Web of Science ®Google Scholar
• Zaru M, Mourtas S, Klepetsanis P, et al. Liposomes for drug delivery to the lungs by nebulization. Eur J Pharm Biopharm 2007;67:655–66
   PubMed Web of Science ®Google Scholar
• Boado RJ, Zhang Y, Zhang Y, Pardridge WM. Humanization of anti-human insulin receptor antibody for drug targeting across the human blood–brain barrier. Biotechnol Bioeng 2007;96:381–91
   PubMed Web of Science ®Google Scholar
• Budai L, Hajdú M, Budai M, et al. Gels and liposomes in optimized ocular drug delivery: studies on ciprofloxacin formulations. Int J Pharm 2007;343:34–40
   PubMed Web of Science ®Google Scholar
• Gupta B, Levchenko TS, Torchilin VP. TAT peptide-modified liposomes provide enhanced gene delivery to intracranial human brain tumor xenografts in nude mice. Oncol Res 2006;16:351–9
   Web of Science ®Google Scholar
• Huwyler J, Wu D, Pardridge WM. Brain drug delivery of small molecules using immunoliposomes. Proc Natl Acad Sci USA 1996;93:14164–9
   PubMed Web of Science ®Google Scholar
• Lee HJ, Engelhardt B, Lesley J, et al. Targeting rat anti-mouse transferrin receptor monoclonal antibodies through blood-brain barrier in mouse. J Pharmacol Exp Ther 2000;292:1048–52
   PubMed Web of Science ®Google Scholar
• Olivier J-C, Huertas R, Lee HJ, et al. Synthesis of pegylated immunonanoparticles. Pharm Res 2002;19:1137–43
   PubMed Web of Science ®Google Scholar
• Pardridge WM, Boado RJ, Kang Y-S. Vector-mediated delivery of a polyamide (“peptide”) nucleic acid analogue through the blood-brain barrier in vivo. Proc Natl Acad Sci USA 1995;92:5592–6
   PubMed Web of Science ®Google Scholar
• Zhang Y, Pardridge WM. Conjugation of brain-derived neurotrophic factor to a blood–brain barrier drug targeting system enables neuroprotection in regional brain ischemia following intravenous injection of the neurotrophin. Brain Res 2001;889:49–56
   PubMed Web of Science ®Google Scholar
• Feng B, Tomizawa K, Michiue H, et al. Delivery of sodium borocaptate to glioma cells using immunoliposome conjugated with anti-EGFR antibodies by ZZ-His. Biomaterials 2009;30:1746–55
   PubMed Web of Science ®Google Scholar
• Gaillard PJ, Appeldoorn CC, Dorland R, et al. Pharmacokinetics, brain delivery, and efficacy in brain tumor-bearing mice of glutathione pegylated liposomal doxorubicin (2B3-101). PLoS One 2014;9:e82331
   PubMed Web of Science ®Google Scholar
• Calvo P, Remunan-Lopez C, Vila-Jato J, Alonso M. Development of positively charged colloidal drug carriers: chitosan-coated polyester nanocapsules and submicron-emulsions. Colloid Polym Sci 1997;275:46–53
   Web of Science ®Google Scholar
• Douglas S, Davis S, Illum L. Nanoparticles in drug delivery. Crit Rev Ther Drug Carrier Syst 1987;3:233–68
   PubMed Web of Science ®Google Scholar
• Garg T, Rath G, Goyal AK. Inhalable chitosan nanoparticles as antitubercular drug carriers for an effective treatment of tuberculosis. Artif Cells Nanomed Biotechnol 2015. [Epub ahead of print]. doi: 10.3109/21691401.2015.1008508
   Web of Science ®Google Scholar
• Gref R, Couvreur P, Barratt G, Mysiakine E. Surface-engineered nanoparticles for multiple ligand coupling. Biomaterials 2003;24:4529–37
   PubMed Web of Science ®Google Scholar
• Kumar S, Jana AK, Dhamija I, Maiti M. Chitosan-assisted immobilization of serratiopeptidase on magnetic nanoparticles, characterization and its target delivery. J Drug Target 2014;22:123–37
   PubMed Web of Science ®Google Scholar
• Garg T, Goyal AK, Arora S, Murthy R. Development, optimization & evaluation of porous chitosan scaffold formulation of gliclazide for the treatment of type-2 diabetes mellitus. Drug Deliv Lett 2012;2:251–61
   Google Scholar
• Garg T, Rath G. Development, optimization and evaluation ofelectrospun nanofibers: tool fortargeted vaginal delivery of antimicrobials against urinary tract infections. Curr Drug Deliv 2015. [Epub ahead of print]. doi: 10.2174/1567201812666150212123348
   Google Scholar
• Kumar A, Garg T, Sarma GS, et al. Optimization of combinational intranasal drug delivery system for the management of migraine by using statistical design. Eur J Pharm Sci 2015;70C:140–51
   Web of Science ®Google Scholar
• Ilium L. Chitosan and its use as a pharmaceutical excipient. Pharm Res 1998;15:1326–31
   PubMed Web of Science ®Google Scholar
• Agnihotri SA, Mallikarjuna NN, Aminabhavi TM. Recent advances on chitosan-based micro-and nanoparticles in drug delivery. J Control Release 2004;100:5–28
   PubMed Web of Science ®Google Scholar
• Chertok B, Moffat BA, David AE, et al. Iron oxide nanoparticles as a drug delivery vehicle for MRI monitored magnetic targeting of brain tumors. Biomaterials 2008;29:487–96
   PubMed Web of Science ®Google Scholar
• Chertok B, David AE, Huang Y, Yang VC. Glioma selectivity of magnetically targeted nanoparticles: a role of abnormal tumor hydrodynamics. J Control Release 2007;122:315–23
   PubMed Web of Science ®Google Scholar
• Tsutsui Y, Tomizawa K, Nagita M, et al. Development of bionanocapsules targeting brain tumors. J Control Release 2007;122:159–64
   PubMed Web of Science ®Google Scholar
• Cheng Q, Feng J, Li F. Brain delivery of neurotoxin-I-loaded nanoparticles through intranasal administration. Acta Pharm Sin 2008;43:431–4
   Google Scholar
• Liu M, Li H, Luo G, et al. Pharmacokinetics and biodistribution of surface modification polymeric nanoparticles. Arch Pharm Res 2008;31:547–54
   PubMed Web of Science ®Google Scholar
• Rao KS, Reddy MK, Horning JL, Labhasetwar V. TAT-conjugated nanoparticles for the CNS delivery of anti-HIV drugs. Biomaterials 2008;29:4429–38
   PubMed Web of Science ®Google Scholar
• Gelperina S, Maksimenko O, Khalansky A, et al. Drug delivery to the brain using surfactant-coated poly (lactide-co-glycolide) nanoparticles: influence of the formulation parameters. Eur J Pharm Biopharm 2010;74:157–63
   PubMed Web of Science ®Google Scholar
• Alyautdin RN, Petrov VE, Langer K, et al. Delivery of loperamide across the blood-brain barrier with polysorbate 80-coated polybutylcyanoacrylate nanoparticles. Pharm Res 1997;14:325–8
   PubMed Web of Science ®Google Scholar
• Wilson B, Samanta MK, Santhi K, et al. Targeted delivery of tacrine into the brain with polysorbate 80-coated poly (n-butylcyanoacrylate) nanoparticles. Eur J Pharm Biopharm 2008;70:75–84
   PubMed Web of Science ®Google Scholar
• Zensi A, Begley D, Pontikis C, et al. Albumin nanoparticles targeted with Apo E enter the CNS by transcytosis and are delivered to neurones. J Control Release 2009;137:78–86
   PubMed Web of Science ®Google Scholar
• Gao H, Qian J, Cao S, et al. Precise glioma targeting of and penetration by aptamer and peptide dual-functioned nanoparticles. Biomaterials 2012;33:5115–23
   PubMed Web of Science ®Google Scholar
• Gao H, Yang Z, Zhang S, et al. Glioma-homing peptide with a cell-penetrating effect for targeting delivery with enhanced glioma localization, penetration and suppression of glioma growth. J Control Release 2013;172:921–8
   PubMed Web of Science ®Google Scholar
• Gao H, Qian J, Yang Z, et al. Whole-cell SELEX aptamer-functionalised poly(ethyleneglycol)-poly(epsilon-caprolactone) nanoparticles for enhanced targeted glioblastoma therapy. Biomaterials 2012;33:6264–72
   PubMed Web of Science ®Google Scholar
• Gao H, Yang Z, Cao S, et al. Behavior and anti-glioma effect of lapatinib-incorporated lipoprotein-like nanoparticles. Nanotechnology 2012;23:435101
   PubMed Web of Science ®Google Scholar
• Gao H, Hu Y, Xiong Y, et al. Glioma targeting and anti-glioma effect of interleukin 13 peptide and RGD peptide dual functionalized nanoparticles. Curr Pharm Biotechnol 2014;14:1118–26
   PubMed Web of Science ®Google Scholar
• Gao H, Xiong Y, Zhang S, et al. RGD and interleukin-13 peptide functionalized nanoparticles for enhanced glioblastoma cells and neovasculature dual targeting delivery and elevated tumor penetration. Mol Pharm 2014;11:1042–52
   PubMed Web of Science ®Google Scholar
• Gao H, Yang Z, Cao S, et al. Tumor cells and neovasculature dual targeting delivery for glioblastoma treatment. Biomaterials 2014;35:2374–82
   PubMed Web of Science ®Google Scholar
• Gao H, Wang Y, Chen C, et al. Incorporation of lapatinib into core-shell nanoparticles improves both the solubility and anti-glioma effects of the drug. Int J Pharm 2014;461:478–88
   PubMed Web of Science ®Google Scholar
• Ruan S, Yuan M, Zhang L, et al. Tumor microenvironment sensitive doxorubicin delivery and release to glioma using angiopep-2 decorated gold nanoparticles. Biomaterials 2015;37:425–35
   PubMed Web of Science ®Google Scholar
• Müller R, Lucks J. Arzneistoffträger aus festen lipidteilchen, feste lipidnanosphären (sln). European patent, 605497; 1996
   Google Scholar
• Zhu X, Huang S, Huang H, et al. In vitro and in vivo anti-cancer effects of targeting and photothermal sensitive solid lipid nanoparticles. J Drug Target 2014;22:822–8
   PubMed Web of Science ®Google Scholar
• Müller RH, Mäder K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery – a review of the state of the art. Eur J Pharm Biopharm 2000;50:161–77
   PubMed Web of Science ®Google Scholar
• Smith A. Evaluation of poly (lactic acid) as a biodegradable drug delivery system for parenteral administration. Int J Pharm 1986;30:215–20
   Web of Science ®Google Scholar
• Du J, Lu W-L, Ying X, et al. Dual-targeting topotecan liposomes modified with tamoxifen and wheat germ agglutinin significantly improve drug transport across the blood−brain barrier and survival of brain tumor-bearing animals. Mol Pharm 2009;6:905–17
   PubMed Web of Science ®Google Scholar
• Yanagië H, Ogata A, Sugiyama H, et al. Application of drug delivery system to boron neutron capture therapy for cancer. Expert Opin Drug Deliv 2008;5:427–43
   PubMed Web of Science ®Google Scholar
• Brioschi AM, Calderoni S, Zara GP, et al. Chapter 11 – Solid lipid nanoparticles for brain tumors therapy: state of the art and novel challenges. Prog Brain Res 2009;180:193–223
   PubMed Web of Science ®Google Scholar
• Müller R, Radtke M, Wissing S. Nanostructured lipid matrices for improved microencapsulation of drugs. Int J Pharm 2002;242:121–8
   PubMed Web of Science ®Google Scholar
• Gill KK, Kaddoumi A, Nazzal S. PEG-lipid micelles as drug carriers: physiochemical attributes, formulation principles and biological implication. J Drug Target 2015;23:222–31
   PubMed Web of Science ®Google Scholar
• Sharma AK, Garg T, Goyal AK, Rath G. Role of microemuslsions in advanced drug delivery. Artif Cells Nanomed Biotechnol 2015. [Epub ahead of print]. doi: 10.3109/21691401.2015.1012261
   Web of Science ®Google Scholar
• Batrakova EV, Kabanov AV. Pluronic block copolymers: evolution of drug delivery concept from inert nanocarriers to biological response modifiers. J Control Release 2008;130:98–106
   PubMed Web of Science ®Google Scholar
• Liu L, Guo K, Lu J, et al. Biologically active core/shell nanoparticles self-assembled from cholesterol-terminated PEG–TAT for drug delivery across the blood–brain barrier. Biomaterials 2008;29:1509–17
   PubMed Web of Science ®Google Scholar
• Soni S, Babbar AK, Sharma RK, Maitra A. Delivery of hydrophobised 5-fluorouracil derivative to brain tissue through intravenous route using surface modified nanogels. J Drug Target 2006;14:87–95
   PubMed Web of Science ®Google Scholar
• Inoue T, Yamashita Y, Nishihara M, et al. Therapeutic efficacy of a polymeric micellar doxorubicin infused by convection-enhanced delivery against intracranial 9L brain tumor models. Neuro-oncology 2009;11:151–7
   PubMed Web of Science ®Google Scholar
• Miura Y, Takenaka T, Toh K, et al. Cyclic RGD-linked polymeric micelles for targeted delivery of platinum anticancer drugs to glioblastoma through the blood-brain tumor barrier. ACS Nano 2013;7:8583–92
   PubMed Web of Science ®Google Scholar
• Garg T, Singh O, Arora S, Murthy R. Dendrimer – a novel scaffold for drug delivery. Int J Pharm Sci Rev Res 2011;7:211–20
   Google Scholar
• Kim JH, Yoon HJ, Sim J, et al. The effects of dendrimer size and central metal ions on photosensitizing properties of dendrimer porphyrins. J Drug Target 2014;22:610–18
   PubMed Web of Science ®Google Scholar
• Esfand R, Tomalia DA. Poly (amidoamine)(PAMAM) dendrimers: from biomimicry to drug delivery and biomedical applications. Drug Discov Today 2001;6:427–36
   PubMed Web of Science ®Google Scholar
• Kailasan A, Yuan Q, Yang H. Synthesis and characterization of thermoresponsive polyamidoamine–polyethylene glycol–poly (d,l-lactide) core–shell nanoparticles. Acta Biomater 2010;6:1131–9
   PubMed Web of Science ®Google Scholar
• Sarkar K, Yang H. Encapsulation and extended release of anti-cancer anastrozole by stealth nanoparticles. Drug Deliv 2008;15:343–6
   PubMed Web of Science ®Google Scholar
• Yang H, Lopina ST. Stealth dendrimers for antiarrhythmic quinidine delivery. J Mate Sci Mater Med 2007;18:2061–5
   PubMed Web of Science ®Google Scholar
• Wiwattanapatapee R, Carreño-Gómez B, Malik N, Duncan R. Anionic PAMAM dendrimers rapidly cross adult rat intestine in vitro: a potential oral delivery system? Pharm Res 2000;17:991–8
   PubMed Web of Science ®Google Scholar
• Jevprasesphant R, Penny J, Attwood D, D'Emanuele A. Transport of dendrimer nanocarriers through epithelial cells via the transcellular route. J Control Release 2014;97:259–67
   Web of Science ®Google Scholar
• Dhanikula RS, Argaw A, Bouchard J-F, Hildgen P. Methotrexate loaded polyether-copolyester dendrimers for the treatment of gliomas: enhanced efficacy and intratumoral transport capability. Mol Pharm 2008;5:105–16
   PubMed Web of Science ®Google Scholar
• Zhang X-Q, Intra J, Salem AK. Conjugation of polyamidoamine dendrimers on biodegradable microparticles for nonviral gene delivery. Bioconjug Chem 2007;18:2068–76
   PubMed Web of Science ®Google Scholar
• He H, Li Y, Jia XR, et al. PEGylated Poly(amidoamine) dendrimer-based dual-targeting carrier for treating brain tumors. Biomaterials 2011;32:478–87
   PubMed Web of Science ®Google Scholar
• Garg T, Kumar A, Rath G, Goyal AK. Gastroretentive drug delivery systems for therapeutic management of peptic ulcer. Crit Rev Ther Drug Carrier Syst 2014;31:531–57
   PubMed Web of Science ®Google Scholar
• Garg T, Rath G, Goyal AK. Comprehensive review on additives of topical dosage forms for drug delivery. Drug Deliv 2014d. [Epub ahead of print]. doi: 10.3109/10717544.2013.879355
   PubMed Web of Science ®Google Scholar
• Garg T, Rath G, Goyal AK. Ancient and advanced approaches for the treatment of an inflammatory autoimmune disease-psoriasis. Crit Rev Ther Drug Carrier Syst 2014;31:331–64
   PubMed Web of Science ®Google Scholar
• Desai N, Trieu V, Yao Z, et al. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res 2006;12:1317–24
   PubMed Web of Science ®Google Scholar
• Foote M. Using nanotechnology to improve the characteristics of antineoplastic drugs: improved characteristics of nab-paclitaxel compared with solvent-based paclitaxel. Biotechnol Annu Rev 2007;13:345–57
   PubMedGoogle Scholar
• Hawkins MJ, Soon-Shiong P, Desai N. Protein nanoparticles as drug carriers in clinical medicine. Adv Drug Deliv Rev 2008;60:876–85
   PubMed Web of Science ®Google Scholar
• Henderson IC, Bhatia V. Nab-paclitaxel for breast cancer: a new formulation with an improved safety profile and greater efficacy. Exp Rev Anticancer Ther 2007;7:919–43
   PubMed Web of Science ®Google Scholar
• Kratz F. Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles. J Control Release 2008;132:171–83
   PubMed Web of Science ®Google Scholar
• Miele E, Spinelli GP, Miele E, et al. Albumin-bound formulation of paclitaxel (Abraxane® ABI-007) in the treatment of breast cancer. Int J Nanomed 2009;4:99–105
   PubMed Web of Science ®Google Scholar
• Paál K, Müller J, Hegedûs L. High affinity binding of paclitaxel to human serum albumin. Eur J Biochem 2001;268:2187–91
   PubMedGoogle Scholar
• Purcell M, Neault J, Tajmir-Riahi H. Interaction of taxol with human serum albumin. Biochim Biophys Acta 2000;1478:61–8
   PubMed Web of Science ®Google Scholar
• Garg T, Rath G, Goyal AK. Biomaterials-based nanofiber scaffold: targeted and controlled carrier for cell and drug delivery. J Drug Target 2014;23:202–21
   PubMed Web of Science ®Google Scholar
• Brown TJ, Shaw PA, Karp X, et al. Activation of SPARC expression in reactive stroma associated with human epithelial ovarian cancer. Gynecol Oncol 1999;75:25–33
   PubMed Web of Science ®Google Scholar
• Kim YW, Park Y-K, Lee J. Expression of osteopontin and osteonectin. J Korean Med Sci 1998;13:652–7
   PubMedGoogle Scholar
• Porter PL, Sage EH, Lane TF, et al. Distribution of SPARC in normal and neoplastic human tissue. J Histochem Cytochem 1995;43:791–800
   PubMed Web of Science ®Google Scholar
• Thomas R, True LD, Bassuk JA, et al. Differential expression of osteonectin/SPARC during human prostate cancer progression. Clin Cancer Res 2000;6:1140–9
   PubMed Web of Science ®Google Scholar
• Trieu V, Damascelli B, Soon-Shiong P, Desai N. SPARC expression in head and neck cancer correlates with tumor response to nanoparticle albumin-bound paclitaxel (nab-paclitaxel, ABI-007, Abraxane). Proc Am Assoc Cancer Res 2006;2006:1050
   Google Scholar
• Desai N, Trieu V, Yao R, et al. SPARC expression in breast tumors may correlate to increased tumor distribution of nanoparticle albumin-bound paclitaxel (ABI-007) vs Taxol. Breast Cancer Research and Treatment. New York, NY: Springer; 2004:S26–7
   Google Scholar
• Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007;357:2666–76
   PubMed Web of Science ®Google Scholar
• Wilson B, Lavanya Y, Priyadarshini SR, et al. Albumin nanoparticles for the delivery of gabapentin: preparation, characterization and pharmacodynamic studies. Int J Pharm 2014;473:73–9
   PubMed Web of Science ®Google Scholar
• Newton HB. Molecular neuro-oncology and development of targeted therapeutic strategies for brain tumors. Part 2: PI3K/Akt/PTEN, mTOR, SHH/PTCH and angiogenesis. Expert Rev Anticancer Ther 2004;4:105–28
   PubMedGoogle Scholar
• Ratcheson RA, Ommaya AK. Experience with the subcutaneous cerebrospinal-fluid reservoir: preliminary report of 60 cases. N Engl J Med 1968;279:1025–31
   PubMed Web of Science ®Google Scholar